Skip to main content

MDSC depletion during immunization with heat-killed Mycobacterium tuberculosis increases protection against BCG infection

Research Abstract

Tuberculosis (TB) remains one of the deadliest infectious diseases globally. Although the approved human Bacille-Calmette-Guérin (BCG) vaccines provide limited protection, a vaccine based on Mycobacterium tuberculosis (Mtb) has yet to be approved. Our previous findings demonstrated that s.c. immunization with heat-killed Mtb significantly increased the number of monocytic myeloid-derived suppressor cells (M-MDSC) in mice. Thus, we hypothesized that the defense against a subsequent BCG infection would be compromised in Mtb-immunized mice. Surprisingly, mice vaccinated with Mtb were protected against BCG infection and exhibited elevated frequencies and activation of dendritic cells (DC) and mycobacteria-specific T cells, despite high frequencies and suppressor activity of M-MDSC. Genetic ablation of CCR2+ monocytic cells or pharmacological intervention with all-trans retinoic acid (ATRA) reduced the frequency of Mtb-induced M-MDSC, enhanced the frequencies and activation of DC and CD4+ T cells, and resulted in decreased bacterial loads in the lungs and spleen. These findings provide new insights into TB vaccination using heat-killed Mtb despite the concurrent unwanted effects of vaccine-induced M-MDSC. M-MDSC depletion via ATRA further shifts the balance toward immunity and should be considered an adjunct host-directed therapy alongside TB vaccines in humans.

Research Authors
Arpa Aintablian, Anna M Arold, Haisam Alattar, Laura Cyran, Christoph Schoen, Nelita Du Plessis, Gerhard Walzl, Ulrich Emil Schaible, Andreas Beilhack, Manfred B Lutz
Research Date
Research Journal
Frontiers in Immunology
Research Pages
Article 1646526
Research Publisher
Frontiers Media S.A.
Research Rank
Q1
Research Vol
16
Research Website
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1646526/full?utm_source=chatgpt.com
Research Year
2025

A TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer

Research Abstract

Tumor-draining lymph nodes (TDLNs) are sites of anti-tumor immune priming as well as metastases. Here, we examined how the cellular networks within TDLNs are reorganized in triple-negative breast cancer (TNBC). We found that the frequencies of programmed death ligand 1 high (PD-L1hi) monocytes increased in TDLNs of metastatic TNBC mouse tumors. Fibroblastic reticular cell (FRC) subtypes heightened the expression of the chemokines CCL2 and CCL7, supporting the homing of CCR2+ monocytes. These monocytes suppressed T cells in vitro via PD-L1 and inducible nitric oxide synthase (iNOS). Spatial transcriptomics revealed immunosuppressive FRC-monocyte niches in vascularized and T cell areas. Tumor-associated Toll-like receptor (TLR) 4 ligands induced CCL2 and CCL7 expression by FRCs to promote monocyte recruitment. Localized TLR4 inhibition in combination with anti-programmed cell death protein 1 (αPD-1) therapy reduced monocyte homing and boosted T cell function, ultimately attenuating lung metastases. Monocytes accumulate in human TNBC TDLNs, with evidence of a FRCmonocyte axis, and a TLR4 ligand signature is predictive of poor survival outcomes in TNBC patients. Thus, metastatic TNBC can reprogram lymph nodes (LNs) to facilitate PD-L1-mediated immune evasion and metastasis.

Research Authors
Greta Mattavelli, Moutaz Helal, Ana Cetkovic, Maximilian J. Krämer, Saskia-Laureen Herbert, Kilian Mielert, Tanja Schlaiss, Anna Frank, Emily Riemer, Mara John, Josefina del Pilar Martinez Vasquez, Laura Kindl, Jonathan J. Swietlik, Benedikt O. Gansen, Ma
Research Date
Research Journal
Immunity
Research Pages
2830–2846.e15
Research Publisher
Elsevier (Cell Press)
Research Rank
Q1
Research Vol
58
Research Website
https://linkinghub.elsevier.com/retrieve/pii/S1074761325003784
Research Year
2025

AMPK Activation Downregulates TXNIP, Rab5, and Rab7 Within Minutes, Thereby Inhibiting the Endocytosis-Mediated Entry of Human Pathogenic Viruses

Research Abstract

Cellular metabolism must adapt rapidly to environmental alterations and adjust nutrient uptake. Low glucose availability activates the AMP-dependent kinase (AMPK) pathway. We demonstrate that activation of AMPK or the downstream Unc-51-like autophagy-activating kinase (ULK1) inhibits receptor-mediated endocytosis. Beyond limiting dextran uptake, this activation prevents endocytic uptake of human pathogenic enveloped and non-enveloped, positive- and negative-stranded RNA viruses, such as yellow fever, dengue, tick-borne encephalitis, chikungunya, polio, rubella, rabies lyssavirus, and SARS-CoV-2, not only in mammalian and insect cells but also in precision-cut lung slices and neuronal organoids. ULK1 activation inhibited enveloped viruses but not EV71. However, receptor presentation at the cytoplasmic membrane remained unaffected, indicating that receptor binding was unchanged, while later stages of endocytosis were targeted via two distinct pathways. Drug-induced activation of the AMPK pathway reduced early endocytic factor TXNIP by suppressing translation. In contrast, the amounts of Rab5 and the late endosomal marker Rab7 decreased due to translation inactivation and ULK1-dependent proteasome activation within minutes. Furthermore, activation of AMPK hindered the late replication steps of SARS-CoV-2 by reducing viral RNAs and proteins and the endo-lysosomal markers LAMP1 and GRP78, suggesting a reduction in early and late endosomes and lysosomes. Inhibition of the PI3K and mTORC2 pathways, which sense amino acid and growth factor availability, promotes AMPK activity and blocks viral entry. Our results indicate that AMPK and ULK1 emerge as restriction factors of cellular endocytosis, impeding the receptor-mediated endocytic entry of enveloped and non-enveloped RNA viruses.

Research Authors
Viktoria Diesendorf, Veronica La Rocca, Michelle Teutsch, Haisam Alattar, Helena Obernolte, Kornelia Kenst, Jens Seibel, Philipp Wörsdörfer, Katherina Sewald, Maria Steinke, Sibylle Schneider-Schaulies, Manfred B. Lutz, Jochen Bodem
Research Date
Research Journal
Cells
Research Pages
334
Research Publisher
MDPI
Research Rank
Web of Science (Clarivate JCR): Q2 // Scopus/SCImago (SJR): Q1
Research Vol
Volume 14, Issue 5
Research Website
https://www.mdpi.com/2073-4409/14/5/334?utm_source=chatgpt.com
Research Year
2025

Meeting of the Department of Pharmacognosy Council at the Faculty of Pharmacy This will take place on Sunday, January 4, 2026

God willing, the 65th meeting of the Department of Pharmacognosy Council at the Faculty of Pharmacy This will take place on Sunday, January 4, 2026, at 11:00 AM.

in the department council meeting room.

news category
خبر عام

Meeting of the Council of the Pharmaceutics Department, Faculty of This will take place on Monday, January 5, 2026.

God willing, the meeting of the Pharmaceutics Department Board of the Faculty of Pharmacy No. (546) This will take place on Monday, January 5, 2026 at 11:00 AM.

in the department board on the third floor under the chairmanship of the Faculty to discuss the topics that we will inform you later.

news category
خبر عام
Subscribe to